CAS 1246213-41-1: N-[5-(1,1-Dimethylethyl)-2,3-dihydro-3,3-dimethyl-2-oxo-6-benzofuranyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide

Ivacaftor is a drug product that is used for the treatment of cystic fibrosis. It is an active ingredient of Kalydeco, which is a combination therapy to treat cystic fibrosis. Ivacaftor is the first FDA-approved drug for the treatment of CF in patients with specific mutations. The metabolism of ivacaftor has been studied by analytical methods and it has been shown to have natural impurities. The API impurity and synthetic impurity standards are available for custom synthesis and can be ordered from a specialty manufacturer. Ivacaftor requires high purity and pharmacopoeia-grade standards for research and development as well as niche markets, such as HPLC standard or high purity.